Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression

Reuters

Jan 07

Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression

Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601872020"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601872020\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601872020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601872020","market":"nz","top_or_hot":-1,"title":"Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9gvZ1j:1","article_id":"2601872020","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601872020","pubTimestamp":1767785628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression  and post-traumatic stress disorder . The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技"},"translate_title":"Compass Pathways发布投资者演示文稿，重点介绍COMP360治疗难治性抑郁症的3期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression\n    \n\n        Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}